CD274 and melanoma: The phenomenon of detecting ICB efficacy through circulating EVs was first identified in melanoma patients treated with pembrolizumab, where plasma PD-L1-EV levels were positively correlated with intracellular Ki-67 levels in CD8+ T cells.